PROTOCADHERIN 7 (PCDH7), a transmembrane receptor and member of the Cadherin superfamily, is frequently overexpressed in lung adenocarcinoma and is associated with poor clinical outcome. While PCDH7 was recently shown to promote transformation and facilitate brain metastasis in lung and breast cancers, decreased PCDH7 expression has also been documented in colorectal, gastric, and invasive bladder cancers. These data suggest context-dependent functions for PCDH7 in distinct tumor types. Given that PCDH7 is a potentially targetable molecule on the surface of cancer cells, further investigation of its role in tumorigenesis in vivo is needed to evaluate the therapeutic potential of its inhibition. Here we report the analysis of novel PCDH7 gain-and loss-of-function mouse models and provide compelling evidence that this cell-surface protein acts as a potent lung cancer driver. Employing a Cre-inducible transgenic allele, we demonstrated that enforced PCDH7 expression significantly accelerates Kras G12D -driven lung tumorigenesis and potentiates MAPK pathway activation. Furthermore, we performed in vivo somatic genome editing with CRISPR/Cas9 in Kras LSL-G12D ; Tp53 fl/fl (KP) mice to assess the consequences of PCDH7 loss of function. Inactivation of PCDH7 in KP mice significantly reduced lung tumor development, prolonged survival, and diminished phospho-activation of ERK1/2. Together, these findings establish a critical oncogenic function for PCDH7 in vivo and highlight the therapeutic potential of PCDH7 inhibition for lung cancer. Moreover, given recent reports of elevated or reduced PCDH7 in distinct tumor types, the new inducible transgenic model described here provides a robust experimental system for broadly elucidating the effects of PCDH7 overexpression in vivo.
AUTHOR SUMMARY
Lung cancer is the leading cause of cancer-associated deaths worldwide. PROTOCADHERIN 7 (PCDH7), cell surface protein and member of the Cadherin superfamily, is frequently overexpressed in lung adenocarcinomas and is associated with poor clinical outcome. Nevertheless, it has yet to be shown in vivo whether PCDH7 plays a role in the initiation and progression of lung cancer, and whether it represents an actionable therapeutic target. Here we demonstrate, using a novel transgenic mouse model, that PCDH7 overexpression accelerates Kras G12D -driven lung tumorigenesis. Furthermore, we validate PCDH7 as a therapeutic target by knocking it out using in vivo somatic genome editing in the Kras LSL-G12D ; Tp53 fl/fl (KP) model. Our results provide new insight into the mechanisms that drive lung cancer pathogenesis and, because targeting oncogenic cell-surface proteins with antibodies has proven to be a highly effective anti-cancer therapeutic strategy, establish a new target for cancer treatment. Moreover, given recent reports of elevated or reduced PCDH7 in distinct tumor types, the transgenic PCDH7 model described here provides a robust experimental system for elucidating the effects of PCDH7 overexpression in different in vivo settings. This model will also provide an ideal system for future testing of therapeutics directed at PCDH7.
INTRODUCTION
Protocadherins (PCDHs) are transmembrane proteins and members of the Cadherin superfamily that play well-established roles in cell adhesion and regulation of downstream signaling pathways (1, 2) . A growing body of evidence has demonstrated that PCDH expression is dysregulated in tumorigenesis (3) (4) (5) (6) (7) . Both oncogenic and tumor suppressive roles have been assigned to PCDHs. However, the roles of individual PCDHs in cancer and the mechanisms through which their gain-of-function and loss-of-function drive tumorigenesis in vivo remain poorly understood. We previously reported that PROTOCADHERIN 7 (PCDH7) is frequently overexpressed in human non-small cell lung cancer (NSCLC) tumors (8) . Moreover, high expression of PCDH7 was associated with poor clinical outcome of lung adenocarcinoma patients.
While PCDH7 was recently shown to mediate brain metastasis in breast and lung cancers (9) (10) (11) (12) , decreased PCDH7 expression has been documented in colorectal, gastric, and invasive bladder cancers (13) (14) (15) . Collectively, these data suggest contextdependent functions for PCDH7 in distinct tumor types. Because this molecule is a cell surface receptor that is potentially accessible to antibody-based therapies, rigorous in vivo studies are needed to interrogate PCDH7 function in cancer pathogenesis.
Lung cancer is the leading cause of cancer-associated deaths worldwide (16) .
Given the limited effectiveness of current treatments, there is a critical need to identify new therapeutic targets. PCDH7 transforms human bronchial epithelial cells (HBECs) and synergizes with KRAS to induce MAPK signaling and tumorigenesis in immunocompromised mice (8) . One mechanism through which PCDH7 potentiates ERK signaling is by facilitating interaction of Protein Phosphatase 2A (PP2A) with its potent inhibitor, the SET oncoprotein, thereby suppressing PP2A activity (8) . Depletion of PCDH7 suppressed ERK activation, sensitized NSCLC cells to MEK inhibitors, and reduced growth of lung cancer cells in xenograft assays. Nevertheless, all prior studies of PCDH7 function in cancer utilized established cell lines. Thus, investigation of the oncogenic activity of PCDH7 in vivo using autochthonous tumor models, which more accurately model multi-stage tumor progression and the role of the tumor microenvironment, is needed to dissect the role of this cell surface receptor in cancer pathogenesis and to evaluate the therapeutic potential of PCDH7 inhibition for nonsmall cell lung cancer.
In this study, we sought to establish the importance of PCDH7 in Kras G12D -driven lung cancer pathogenesis. To examine the effects of PCDH7 upregulation in lung tumor initiation and progression, we generated an inducible PCDH7 transgenic mouse model, allowing the demonstration that hyperactivity of PCDH7 promoted lung tumorigenesis and induced MAPK pathway activation in Kras LSL-G12D mutant mice (17) . Additionally, to validate PCDH7 as a therapeutic target, we performed in vivo somatic gene editing in Kras LSL-G12D ; Tp53 fl/fl (KP) mice (18) . Somatic depletion of PCDH7 in KP mice with CRISPR/Cas9 significantly reduced lung tumor development and prolonged survival, suggesting that targeting PCDH7 may benefit patients with lung adenocarcinoma.
Interrogation of downstream signaling pathways revealed diminished phospho-ERK1/2 and phospho-RB in PCDH7 knockout tumors. These findings demonstrate a key oncogenic role for PCDH7 in vivo, supporting the potential therapeutic efficacy of PCDH7 inhibition for patients with lung cancer.
RESULTS

PCDH7 accelerates lung tumorigenesis in a mouse model of Kras G12D -driven lung adenocarcinoma
To assess the oncogenic activity of PCDH7 in vivo and to investigate the mechanisms underlying PCDH7-mediated transformation, we generated a transgenic mouse model that allows precise control of PCDH7 expression through Cre-mediated recombination.
We selected human PCDH7 isoform A, which is the predominant isoform expressed in human lung cancer cell lines from the Cancer Cell Line Encyclopedia and a panel of NSCLC cell lines (8, 19) . The transgene is depicted in Fig 1A. Replication-deficient viruses have been widely used to deliver Cre to the lung, thereby activating a mutant Kras allele to generate sporadic lung tumors in Kras mice (17, (20) (21) (22) . To determine whether enforced expression of PCDH7 is sufficient to accelerate Kras G12D -mediated lung tumorigenesis in vivo, we bred PCDH7 LSL mice with Kras LSL-G12D mice and induced both transgenes via intratracheal administration of Adenovirus-Cre (23) (Fig 1A) . Tumors were detectable in all lobes at 16 and 20 weeks post-infection (Fig 1B) . At 16 weeks post-infection, the majority of tumors were earlystage and categorized as atypical adenomatous hyperplasia (AAH) or bronchiolar hyperplasia (BH) (17, 18, 23) (Fig 1C and S1D Fig) . Kras LSL-G12D ; PCDH7 LSL/LSL mice exhibited a significant increase in AAH and BH tumors compared to Kras LSL-G12D mice.
Kras LSL-G12D ; PCDH7 LSL/LSL mice also developed more adenomas than Kras LSL-G12D mice, indicating accelerated disease progression. At 20 weeks post-infection, tumor burden was significantly higher in Kras LSL-G12D ; PCDH7 LSL/LSL mice than in Kras LSL-G12D mice, as determined by quantifying tumor numbers at different stages ( Fig 1C) and lung weight ( Fig 1D and S1E Fig) . No tumors were observed in PCDH7 LSL/LSL mice after 16 months post-infection, suggesting that isolated expression of the transgene is not sufficient to initiate tumorigenesis by this time-point.
PCDH7 cooperates with oncogenic KRAS to promote ERK activation and cell proliferation in human bronchial epithelial cells (HBECs) (8) . Consistent with these effects, tumors from Kras LSL-G12D ; PCDH7 LSL/LSL mice exhibited increased levels of Ki67 and pERK1/2 staining compared to tumors from Kras LSL-G12D mice (Fig 1E-G) . Taken together, these data support a pro-tumorigenic role for PCDH7 in Kras G12D -mutant lung cancer and demonstrate that PCDH7 modulates MAPK pathway activity in vivo.
In vivo inactivation of Pcdh7 reduces lung tumor burden and prolongs survival of
Kras LSL-G12D ; Tp53 fl/fl mice
Inhibition of PCDH7 reduced tumorigenesis of KRAS mutant NSCLC cells in xenograft assays (8) . However, xenografts do not fully recapitulate all aspects of tumorigenesis, including contributions from the microenvironment and immune system. Therefore, examination of in vivo loss-of-function is critical to establish whether PCDH7 represents a potential therapeutic target in NSCLC. We took advantage of a recently described in vivo somatic genome editing approach to rapidly interrogate PCDH7 function in Kras LSL-G12D ;Tp53 fl/fl (KP) mice (Fig 2A) (18) . Interestingly, PCDH7 is upregulated in KP tumors relative normal lung, suggesting it may act as an oncogenic driver in this context (S2A To identify an optimal Pcdh7 single-guide (sgRNA) for in vivo studies, immortalized mouse embryonic fibroblasts were infected with a lentivirus expressing the Cas9 nuclease and a control sgRNA or one of five sgRNAs directed against murine Pcdh7 (Fig 2A) (24) . (Fig 2B) . At an early time-point (ten weeks after infection), we observed fewer adenomas but not AAH or BH lesions in Pcdh7-targeted KP lungs ( Fig. 
2C-D), suggesting that depletion of PCDH7 impairs tumor progression. Moreover, at 20
weeks post-infection, a time-point associated with robust adenocarcinoma formation in KP mice, we documented significantly reduced tumor burden (Fig 2E-G) .
Given recent studies documenting a role for PCDH7 in metastasis, we assessed invasive properties of tumors in these mice. We observed evidence of micro-and macro-metastases, lymphovascular invasion, and intravascular tumor spreading in control-treated Kras LSL-G12D ; Tp53 fl/fl mice (S3 Fig). sg-Pcdh7-treated mice exhibited a lower incidence of these malignant features and a higher incidence of relatively benign neoplastic lesions, including AAH and adenomas. Thus, Pcdh7 depletion reduced tumor invasiveness in vivo.
To verify gene editing events, genomic DNA was harvested from Pcdh7-targeted tumors at 20 weeks after infection, mutations in the sgRNA-targeted region of Pcdh7 were sequenced, and PCDH7 expression was measured by western blotting. All control tumors from Kras LSL-G12D ; Tp53 fl/fl mice expressed high levels of PCDH7 relative to normal lung tissue ( Fig 3A) . As expected, tumors isolated from sg-Pcdh7-targeted KP mice exhibited diminished PCDH7 expression to varying degrees across analyzed tumors (Fig 3A and S4A Fig) 
Somatic knockout of Pcdh7 inhibits proliferation and reduces MAPK signaling in
Kras LSL-G12D ; Tp53 fl/fl mice
To examine the effects of PCDH7 depletion on downstream signaling in vivo, we harvested tumors from KP mice infected with either sg-control or sg-Pcdh7 lentivirus and analyzed phospho-ERK1/2 and total ERK expression by western blotting (Fig 3A) .
Although phospho-ERK1/2 was uniformly lower in sg-Pcdh7-targeted tumors compared to control tumors, some heterogeneity existed, consistent with additional genetic events affecting the MAPK pathway. Immunohistochemistry demonstrated that pERK1/2 and Ki67 staining were reduced in tumors from sg-Pcdh7-targeted mice compared to control KP tumors (Fig 3B-D) , further supporting a role for PCDH7 in stimulating MAPK pathway activity.
PCDH7 modulates expression of PP2A targets
PCDH7 overexpression in HBECs impact several important cancer-relevant pathways.
One reported target of PP2A is pRB (26) . Accordingly, the pRB pathway was previously identified as a significantly upregulated gene set in RNAseq analysis of HBEC-shp53-PCDH7 cells (p=0; FDR q value = 2.35 x 10 -4 ) (8). To determine whether PCDH7 regulates the pRB pathway in the context of mutant KRAS G12V , we generated HBEC-shp53 cells with enforced expression of mutant KRAS G12V , PCDH7, or both in combination. Western blot analysis revealed that while KRAS G12V increased pERK and pRB signaling, PCDH7 cooperated with KRAS G12V to further enhance both pERK and pRB signaling (Fig 4A) . Furthermore, both pERK and pRB signaling were significantly reduced upon PCDH7 inhibition with siRNAs in shp53-KRAS G12V -PCDH7 cells (Fig 4B) .
To determine the extent to which PCDH7 inhibition impacts the RB pathway in vivo, sg-control or sg-Pcdh7-treated tumors from KP mice were collected at 20 weeks post-infection, and pRB and total RB were examined by western blotting. A minor, but significant, decrease in pRB signaling was observed in PCDH7-depleted tumors compared to control tumors (Fig 4C-D) . Finally, we extended these studies to human NSCLC xenografts. In KRAS mutant H1944 lung adenocarcinoma cells, CRISPR/Cas9mediated depletion of PCDH7 suppressed the growth of xenografts in immunocompromised NOD/SCID IL2Rg null NSG mice (8) . Western blotting demonstrated that PCDH7 depletion diminished both pRB and pERK signaling in vivo (Fig 4E) .
Collectively, these data show that PCDH7 enhances phosphoactivation of multiple PP2A targets including pERK1/2, and to a lesser extent pRB, in KRAS-mutant lung cancer cells.
DISCUSSION
PCDH7 is an actionable therapeutic target in lung adenocarcinoma
The inducible PCDH7 transgenic mouse described here provides a valuable model for the evaluation of PCDH7 function in various tumorigenic contexts. Given the prior reports of elevated or reduced PCDH7 in distinct tumor types (8, 10, (13) (14) (15) , the PCDH7 LSL model, when combined with various tissue-specific Cre driver lines, provides a robust experimental system for elucidating the effects of PCDH7 overexpression in different in vivo settings. Furthermore, this animal model represents an ideal system for future testing of therapeutics directed at PCDH7, including monoclonal antibodies.
We previously demonstrated that PCDH7 interacts with the PP2A phosphatase, and SET (a potent PP2A inhibitor), thereby inhibiting PP2A activity in HBECs and human NSCLC cells (8) . PP2A loss of function results in aberrant phosphorylation of substrates in a variety of pathways linked to cancer, including the MAPK, RB, AKT, and JAK/STAT pathways (27) (28) (29) (30) . Our in vivo gain-and loss-of-function studies demonstrate that PCDH7 promotes ERK phosphoactivation, an event known to initiate lung tumorigenesis and promote the rapid progression of adenomas to more invasive adenocarcinomas (31) . Importantly, the magnitude and duration of ERK signaling are tightly controlled by regulators that provide negative feedback, including PP2A (32, 33) .
Moreover, the consequences of PCDH7-mediated PP2A inhibition likely extend beyond MAPK signaling. Indeed, we show here that PCDH7 modulates pRB levels in human NSCLC xenografts and, to a lesser extent, in KP mouse tumors. Taken together, our data establish PCDH7 as a cooperative oncogenic driver in KRAS-mutant lung cancer that functions to enhance pro-tumorigenic signaling in cancer cells.
PCDH7 was recently shown to promote metastasis of lung and breast cancer cells (10, 34) , further supporting the importance of this protein in multiple aspects of tumor biology. Consistent with these observations, our studies revealed that Pcdh7 depletion in KP mice reduced tumor invasiveness in vivo. Overall, the results reported here establish PCDH7 as an oncogenic driver of lung tumor initiation and progression in vivo, setting the stage for future efforts to target this cell-surface protein with novel therapeutic strategies in lung adenocarcinoma.
MATERIALS AND METHODS
Constructs
Human PCDH7 isoform-A (NM_002589.2) cDNA was cloned into the CTV vector (Addgene #15912). The resulting CTV-PCDH7 was used to generate transgenic mice. Ethics Statement. Mice were monitored closely throughout all experimental protocols to minimize discomfort, distress, or pain. Signs of pain and distress include disheveled fur, decreased feeding, significant weight loss (>20% body mass), limited movement, or abnormal gait. If any of these signs were detected, the animal was removed from the study immediately and euthanized. All sacrificed animals were euthanized with CO2.
The animals were placed in a clear chamber and 100% CO2 was introduced. Animals independent fields were quantified for each animal.
Tumor burden analysis
For tumor quantification ( Figure 1C and 2D) , the total tumor number for each animal was determined by analyzing H&E staining and categorizing tumors into different stages. 5 lobes per animal were quantified, and 5-6 animals were analyzed per group.
To analyze tumor burden of CRISPR/Cas9-targeted mice ( Figure 2F and 2G units/ml of penicillin and streptomycin (Life Technologies, Inc.). PCDH7 depletion in H1944 cells was achieved using Lenti-CRISPRv2 followed by selection with puromycin for 7 days (1 μg/mL). All cell lines used in this study were cultured in 5% CO2 at 37C and tested negative for mycoplasma contamination.
Virus preparation, titration and intratracheal administration
Cre-expressing adenovirus (Adeno-Cre) was purchased from Viral Vector Core Facility (University of Iowa). The PCDH7 LSL and Kras LSL-G12D transgenes were induced with intratracheal administration of Adenovirus-Cre (Adeno-Cre, 2x10 7 IFU/mouse) (23) .
Pcdh7 sgRNA-1 (sg-Pcdh7) or a non-specific control sgRNA (sg-control) were cloned into pSECC lentiviral vectors, packaged, and titered with Green-Go cells as previously described (18) 
Verification of gene editing
To detect CRISPR-induced indels, tumors from a sg-Pcdh7 mouse (20 weeks after infection) were dissected and surrounding lung tissues carefully removed. Tumor tissues were homogenized, and genomic DNA (gDNA) was isolated using the Gentra Puregene Tissue Kit (Qiagen). To amplify the Pcdh7 sgRNA-targeted region, PCR was performed with tumor gDNA using PrimeSTAR HS DNA Polymerase (Clontech). The products were gel purified and cloned into the Zero Blunt TOPO sequencing vector (Invitrogen). At least eight colonies for each tumor were sequenced.
Statistical Analysis
All statistical analyses were performed using GraphPad Prism for Windows. 
